Revvity Inc Stock Price, News & Analysis

Revvity (NYSE:RVTY) has announced a significant program to expand its type 1 diabetes (T1D) testing capabilities, partnering with Sanofi. The initiative includes developing a T1D 4-plex in vitro diagnostic (IVD) assay based on their existing 3-plex research-use assay.

The program aims to enable population-scale screening for early-stage T1D using Revvity's GSP® instrument with both capillary dried blood spot and venous specimens. The company plans regulatory submissions to the U.S. FDA, IVDR, and other major jurisdictions. Additionally, Revvity will expand its laboratory network globally to increase access to its existing research-use product, currently offered as an LDT at their CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh.

This initiative addresses a significant medical need, as over 9 million people worldwide live with T1D, with more than 500,000 new cases diagnosed annually, 90% without family history.

Revvity (NYSE:RVTY) has launched Living Image™ Synergy AI, a groundbreaking multimodal analysis software for in vivo imaging research. The platform unifies data analysis across optical, microCT, and ultrasound modalities, integrating advanced AI capabilities to enhance preclinical imaging analysis.

The software aims to streamline workflows by centralizing analysis tools, automating image segmentation, and providing intuitive co-registration capabilities. Key features include automated ROI quantification, reduced manual tasks, and enhanced reproducibility across studies. The platform will be showcased at the WMIC conference in Anchorage, Alaska from September 29 to October 3, 2025.

Revvity (NYSE:RVTY) has announced a strategic collaboration with Profluent to enhance its Pin-point™ base editing platform with AI-engineered enzymes. The partnership combines Profluent's AI-designed proteins with Revvity's established technology to create a more precise and efficient gene editing toolkit.

The enhanced Pin-point platform achieves single nucleotide precision without bystander editing and requires ultra-low amounts of deaminase while maintaining clinical editing levels. This collaboration follows Revvity's successful integration of Profluent's OpenCRISPR™ nuclease into the Pin-point system, previously published in Nature.

The new system will be available through bundled licensing, aiming to accelerate the development of gene therapies. Revvity will showcase this technology at the ESGCT 2025 Annual Congress in Seville, Spain.

Revvity (NYSE:RVTY) has announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina's Research Triangle. The state-of-the-art facility consolidates R&D teams specializing in software, hardware, applied biology, machine learning, optical, microCT, and ultrasound technologies.

The center showcases Revvity's latest innovations including the IVIS™ optical imaging systems, Quantum™ GX3 microCT system, Vega™ automated preclinical ultrasound system, and VivoJect™ Image-Guided Injection System. The facility aims to accelerate innovation in disease research workflows and advance next-generation imaging instruments while offering live demos and training opportunities for visitors.

Revvity (NYSE:RVTY) has announced its participation in two upcoming investor conferences in September 2025. The company's CFO Max Krakowiak will present at the Wells Fargo Healthcare Conference on September 3 at 8:00 a.m. ET, while SVP Steve Willoughby will participate in the Baird Global Healthcare Conference on September 9 at 2:35 p.m. ET.

Both presentations will be conducted as fireside chats, providing updates on the company's strategic priorities. The sessions will be available via live audio webcasts on Revvity's website, with replays accessible for at least 30 days following the events.

Revvity (NYSE:RVTY) has launched pHSense™ reagents, an innovative technology designed to advance internalization studies in drug discovery, particularly for G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs).

The new technology offers high-throughput, plate-based workflows with enhanced detection capabilities, combining pH-sensitive dye and time-resolved fluorescence (TRF) readout. The reagents are fully compatible with Revvity's multimode detection platforms and aim to accelerate preclinical development timelines while reducing costs.

This launch addresses critical limitations in current internalization assay technologies, providing improved data quality, throughput, and reproducibility, particularly beneficial for oncology and precision medicine research.

Revvity (NYSE:RVTY) reported its Q2 2025 financial results, demonstrating growth despite market challenges. The company achieved revenue of $720 million, representing a 4% reported growth and 3% organic growth compared to the previous year. GAAP EPS reached $0.46, while adjusted EPS from continuing operations was $1.18.

The company's performance was driven by two segments: Life Sciences, which generated revenue of $366 million (5% growth), and Diagnostics, which contributed $354 million (3% growth). Based on these results, Revvity raised its full-year 2025 revenue guidance to $2.84-$2.88 billion with projected organic growth of 2-4%, and updated its adjusted EPS guidance to $4.85-$4.95.

Revvity (NYSE:RVTY) has announced its regular quarterly dividend payment. The company's Board of Directors has declared a dividend of $0.07 per share of common stock. The dividend will be paid on November 7, 2025, to shareholders of record as of the close of business on October 17, 2025.

Revvity (NYSE:RVTY) has scheduled its second quarter 2025 earnings release and conference call for Monday, July 28, 2025. The financial results will be released before the market opens, followed by a conference call at 8:00 a.m. ET. The call will be hosted by CEO Prahlad Singh and CFO Max Krakowiak, with a live audio webcast available on the company's Investors website section.